Tirzepatide Physician in Maryland
How GLP-1 Receptor Agonists Benefit Kidney and Heart Health
GLP-1 receptor agonists have transformed type 2 diabetes care. They lower blood sugar, reduce cardiovascular risks, and now show promise for kidney health. A recent Lancet meta-analysis highlights these benefits, offering insights into how these medications can protect vital organs.
Published
Categorized as Diabetes Care, Dr. Tashko’s Key Clinical Trials, GLP1 agonist, Heart Health, Kidney Health
SURMOUNT-1 Trial: Tirzepatide for Treating Obesity and Preventing Diabetes
Tirzepatide has emerged as a game-changing treatment for obesity and diabetes prevention. This three-year study, an extension of the SURMOUNT-1 trial, highlights its ability to deliver sustained weight loss and significantly lower the risk of type 2 diabetes in individuals with both obesity and prediabetes.
Published
SUMMIT Trial: Tirzepatide Reduces Heart Failure Risk in Patients with Obesity
The SUMMIT trial investigated how tirzepatide (Mounjaro or Zepbound), a weight-loss medication, affects heart failure with preserved ejection fraction (HFpEF) in patients with obesity. HFpEF, where the heart pumps effectively but struggles to fill properly, is more common in individuals with high body mass index (BMI). Researchers aimed to determine whether tirzepatide could improve cardiovascular outcomes and enhance quality of life for this population.
Published
History of GLP-1: From Discovery to Revolutionary Treatment
The discovery of GLP-1 transformed diabetes treatment and opened possibilities for addressing other health challenges. What began as a search for proglucagon-derived peptides led to groundbreaking drugs. GLP-1’s journey showcases the impact of scientific breakthroughs.
Published
Categorized as Diabetes Care, Dr. Tashko’s History Notes, GLP1 agonist, Insights from Dr. Tashko, Physiology, Weight Loss
GLP-1: A Surprising Friend Against Cancer in Type 2 Diabetes?
New research suggests diabetes drugs known as GLP-1 receptor agonists (GLP-1) might protect against certain cancers. This study focused on type 2 diabetes patients and followed them for 15 years. It’s a surprising finding that could change cancer prevention for diabetes patients.
Published
Tirzepatide: A Double Approach to Diabetes and Weight Loss
Tirzepatide is a groundbreaking therapy gaining attention for treating type 2 diabetes and obesity. Unlike traditional drugs that target one pathway, tirzepatide uses two hormones, GLP-1 and GIP, to achieve a fuller metabolic control.
Published
Categorized as Diabetes Care, GLP1 agonist, Insights from Dr. Tashko, Tirzepatide Patient Information, Weight Loss
Muscle Loss and GLP-1 Agonists: What You Need to Know
While GLP-1 agonists offer exciting potential, some patients worry about their effects on muscle mass during weight loss. Let’s break down what’s happening in the body when using these medications, and how to protect your muscles.
Published
Categorized as GLP1 agonist, Insights from Dr. Tashko, Insulin Resistance, Muscle Physiology, Weight Loss
Eating Smart on GLP-1: 10 Strategies for Successful Weight Loss
The GLP-1 medications—like tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy)—have become powerful allies in weight loss. They work by reducing appetite, enhancing insulin response, and supporting a balanced metabolism. But to make the most of these treatments, eating smart is essential.
Published
Categorized as GLP1 agonist, Insights from Dr. Tashko, Insulin Resistance, Nutritional Guidance, Obesity Care, Weight Loss
Tirzepatide: A Dual Solution for Obstructive Sleep Apnea and Obesity
Obstructive sleep apnea (OSA) is characterized by disordered breathing during sleep and is associated with significant cardiovascular complications. Excess body fat, or adiposity, is a primary risk factor for OSA. The SURMOUNT study explores the potential of tirzepatide (branded as Mounjaro or Zepbound) as a treatment for OSA in obese individuals through two phase 3, double-blind, randomized, controlled trials.
Published
The SYNERGY Study on Tirzepatide: A Game-Changer for MASH Treatment
Metabolic dysfunction–associated steatohepatitis (MASH), formerly called nonalcoholic steatohepatitis (NASH), is a severe liver disease. MASH involves fat buildup, liver inflammation, and cell injury, often leading to fibrosis. With rising obesity and type 2 diabetes, MASH cases are growing globally.
Published